|Bid||76.40 x 1800|
|Ask||77.25 x 3000|
|Day's range||75.99 - 77.46|
|52-week range||68.44 - 83.78|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||27.89|
|Forward dividend & yield||2.60 (3.37%)|
|Ex-dividend date||14 Jun 2021|
|1y target est||N/A|
Andy Slavitt, former White House COVID-19 Response Team adviser, author of ‘PREVENTABLE: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response’, joins Yahoo Finance to discuss the COVID-19 response in the U.S. and the Supreme court upholding the Affordable Care Act.
After a long year and a half spent enduring the coronavirus pandemic, signs of normalcy are starting to show in many U.S. businesses and communities, thanks in part to pharmaceutical breakthroughs including vaccines. After two previously failed attempts to develop new antiviral treatments, biopharma giant Merck (NYSE: MRK) has come up with something it believes will provide care for those in need. Specifically, Merck has been collaborating with Ridgeback Biotherapeutics on a clinical development program for molnupiravir, an oral antiviral medication.
In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.